Key facts
- This page summarizes Tina Marriott's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
- 3 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 23 Feb 2024, 19:22.
Tina Marriott - 22 Feb 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Reporting relationship
- President and COO
- Issuer ticker
- RXRX
- Reported as of
- 22 Feb 2024
- Net transaction value
- -$110,680
- SEC form
- 4
- Accepted by SEC
- 23 Feb 2024, 19:22:51 UTC
- Prior SEC filing
- 16 Feb 2024
- Next SEC filing
- 25 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Nathan Hatfield, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Tina Marriott filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 23 Feb 2024.
Change
- Previous filing in this sequence was filed on 16 Feb 2024.
- Current net transaction value: -$110,680.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RXRX
transaction
Class A Common Stock
Options Exercise
- Transaction value
- $8,480
- Shares
- +8,000
- Change %
- +1.3%
- Price
- $1.06
- Shares after
- 647,982
- Date
- 22 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
RXRX
transaction
Class A Common Stock
Sale
- Transaction value
- $119,160
- Shares
- -8,000
- Change %
- -1.2%
- Price
- $14.90
- Shares after
- 639,982
- Date
- 22 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RXRX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -8,000
- Change %
- -1.6%
- Price
- $0.000000
- Shares after
- 496,000
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 8,000
- Exercise price
- $1.06
- Footnotes
- F4
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 434,122
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $8.55
- Footnotes
- F3
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 159,226
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $11.40
- Footnotes
- F5
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,784
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $11.40
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 150,000
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $2.48
- Footnotes
- F6
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 447,917
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $10.09
- Footnotes
- F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023.
Footnote F2
This transaction was executed in multiple trades at prices ranging from $14.42 to $15.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F3
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Footnote F4
Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
Footnote F5
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Footnote F6
One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
Footnote F7
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.